Filing Details

Accession Number:
0000899243-18-028605
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-11-09 17:06:30
Reporting Period:
2018-11-07
Accepted Time:
2018-11-09 17:06:30
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1088856 Corcept Therapeutics Inc CORT Pharmaceutical Preparations (2834) 770487658
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1232237 S Robert Fishman C/O Corcept Therapeutics Incorporated
149 Commonwealth Drive
Menlo Park CA 94025
Chief Medical Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2018-11-07 8,000 $3.51 8,000 No 4 M Direct
Common Stock Disposition 2018-11-07 8,000 $13.74 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2018-11-07 8,000 $0.00 8,000 $3.51
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
329,000 2025-09-29 No 4 M Direct
Footnotes
  1. These transactions were made pursuant to the terms of a 10b5-1 plan in effect at the time of sale of the shares.
  2. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $13.36 to $13.93 per share. Detailed information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.
  3. Shares subject to this stock option vest and become exercisable at the rate of 25% of the total number at the first anniversary of September 28, 2015. Thereafter, 1/48th of the total number of shares subject to this option grant vests and becomes exercisable on each monthly anniversary, so that the total number of shares subject to this option becomes fully vested and exercisable on September 28, 2019.